Clinical Effect of Prazosin Hydrochloride in Patient with Benign Prostatic Hypertrophy.
- Author:
Hyung Suk SEO
1
;
Joong Ho SHIN
Author Information
1. Department of Urology, Soon Chun Hyang University, College of Medicine, Chun-An Hospital, Chun An, Korea.
- Publication Type:Original Article
- Keywords:
prazosin;
BPH
- MeSH:
Humans;
Prazosin*;
Prostatic Hyperplasia*
- From:Korean Journal of Urology
1989;30(4):509-513
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The clinical effect of prazosin, an alpha-1-receptor blocking agent, was studied in 31 patients with benign prostatic hypertrophy. The daily dose of 1.5-6 mg of prazosin was given for 2 weeks to 3 months. The efficacy was assessed by using uroflowmetry calculated from maximum flow rate, average flow rate and residual urine volume. The result revealed significant improvement of day time frequency, night time frequency (p<0.05) and maximum and average flow rate (p<0.05). It was suspected that prazosin was the valuable alpha-1-receptor blocker for benign prostatic hypertrophy and worth while to initiate medical treatment before undergoing any surgical intervention or when surgery is contraindicated.
